Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Regeneron Pharmaceuticals Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.53, while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $812.27 |
52-Week Low | $25.59 | $545.94 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.86, up 2.51% today, with a bullish technical signal but bearish moving averages. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. The stock shows strong momentum with RSI_6 at 80.23 indicating overbought conditions, while support and resistance cluster around $30-$31.
The outlook for KARS is mixed; positive EV industry trends support growth, but high RSI suggests near-term pullback risk. Investment opportunity lies in global EV expansion, while risks include U.S. market hesitation and competitive pressures from Chinese automakers.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
